ASPECTS OF MULTICOMPONENT THERAPY AND PERIOPERATIVE TACTICS IN A PATIENT WITH ATRIAL FIBRILLATION RECEIVING RIVAROXABAN THERAPY. CLINICAL OBSERVATION
https://doi.org/10.21518/2307-1109-2019-1-62-71
Abstract
The use of modern oral anticoagulants is associated with a significant reduction in the risk of stroke and systemic embolism in patients with atrial fibrillation, and thus with an increase in the life expectancy of patients. That is why multicomponent therapy and perioperative tactics are actual during prolonged anticoagulation, the aspects of which seem to be one of the most difficult from the practical point of view. This clinical observation is an illustration of the management of a patient with atrial fibrillation at high thromboembolic risk who is receiving Rivaroxaban therapy and who has indications for catheter ablation and multicomponent antithrombotic therapy.
About the Authors
O. A. Zemlyanskaya
Federal state budget organization «National medical research center of cardiology» of the Ministry of healthcare
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Department of Clinical Problems of Atherothrombosis of the Institute of Clinical Cardiology named after A. L. Myasnikov
tel.: +7 (916) 563-77-38
121552, Moscow, 3rd Cherepkovskaya St., house 15A
E. S. Kropacheva
Federal state budget organization «National medical research center of cardiology» of the Ministry of healthcare
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Department of Clinical Problems of Atherothrombosis of the Institute of Clinical Cardiology named after A. L. Myasnikov
tel.: +7 (495) 150-44-19
121552, Moscow, 3rd Cherepkovskaya St., house 15A
References
1. Kannel W.B., Abbott R.D., Savage D.D., et al. Epidemiologic features of atrial fibrillation: the Framingham study. N Engl J Med. 1982;306:1018–1022.
2. Feinberg W., Seeger J., Carmody R., Anderson D.C., Hart R.G., Pearce L.A. Epidemiologic features of asymptomatic cerebral infarction in patients with nonvalvular atrial fibrillation. Arch. Intern. Med. 1990;150:2340-2344.
3. Calkins H., Reynolds M.R., Spector P., Sondhi M., Xu Y., Martin A., Williams C.J., Sledge I. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ. Arrhythm. Electrophysiol. 2009;2(4):349–361. DOI: 10.1161/CIRCEP.108.824789.
4. Ruff C.T., Bhatt D.L. , Steg P.G., Gersh B.J., Alberts M.J., Hoffman E.B., Ohman E.M., Eagle K.A., Lip G.Y., Goto S.; REACH Registry Investigators. Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. Int J Cardiol. 2014 Jan 1;170(3):413-8. doi: 10.1016/j.ijcard.2013.11.030.
5. HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation, Hugh Calkins et al., 2017.
6. Natale A., Newby K.H., Pisano E., et al. Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter. J Am Coll Cardiol. 2000;35:1898-1904.
7. Douketis J.D., Spyropoulos A.C., Kaatz S., et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med. 2015;373:823-833.
8. Ellis K., Wazni O., Marrouche N., et al. Incidence of atrial fibrillation post-cavotricuspid isthmus ablation in patients with typical atrial flutter: left-atrial size as an independent predictor of atrial fibrillation recurrence. J Cardiovasc Electrophysiol. 2007;18:799–802.
9. Siklody C., Deneke T., Hocini M., et al. Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation: comparison of different atrial fibrillation ablation technologies in a multicenter study. J Am Coll Cardiol. 2011;58(7):681-688.
10. Voight J., Akkaya M., Somasundaram P., et al. Risk of newonset atrial fibrillation and stroke after radiofrequency ablation of isolated, typical atrial flutter. Heart Rhythm. 2014;11:1884-1889.
11. Haines D., Stewart M., Dahlberg S., et al. Microembolism and catheter ablation I: A comparison of irrigated radiofrequency and multielectrode-phased radiofrequency catheter ablation of pulmonary vein ostia. Circ Arrhythm Electrophysiol. 2013;6:16–22.
12. Kannel W.B., Abbott R.D., Savage D.D., et al. Epidemiologic features of atrial fibrillation: the Framingham study. N Engl J Med. 1982;306:1018–1022.
13. Heidbuchel H., Verhamme R., Alings M., et al. EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013;34(27):2094-106.
14. Calkins H., Reynolds M.R., Spector P., Sondhi M., Xu Y., Martin A., Williams C.J., Sledge I. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ. Arrhythm. Electrophysiol. 2009;2(4):349–361. DOI: 10.1161/CIRCEP.108.824789.
15. Dillier R., Ammar S., Reents T. et al. Safety and Efficacy of Continuous Periprocedural Rivaroxaban for Patients Undergoing Catheter Ablation Procedures: A Retrospective Registry Analysis. Heart Rhythm. 2013;Abstract #PO03-127.
16. HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation, Hugh Calkins et al., 2017.
17. Lakkireddy D., Reddy M., Swarup V., Baqdunes M.W., Mansour M., Chaloub F., Ruskin J., DiBiase L., Vallakatti A., Janga P., Umbarger L. Uninterrupted rivaroxaban vs. warfarin for periprocedural anticoagulation during atrial fibrillation ablation: A multicentre experience. Heart Rhythm. 2013;10(5S):S74.
18. Douketis J.D., Spyropoulos A.C., Kaatz S., et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med. 2015;373:823-833.
19. Lakkireddy D., Reddy Y., Di Biase L., et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective study. J Am Coll Cardiol. 2014;63:982–988.
20. Siklody C., Deneke T., Hocini M., et al. Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation: comparison of different atrial fibrillation ablation technologies in a multicenter study. J Am Coll Cardiol. 2011;58(7):681-688.
21. Cappato R., Marchlinski F.E., Hohnloser S.H. et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015 Jul 21;36(28):1805-11. https://doi.org/10.1093/eurheartj/ehv177.
22. Haines D., Stewart M., Dahlberg S., et al. Microembolism and catheter ablation I: A comparison of irrigated radiofrequency and multielectrode-phased radiofrequency catheter ablation of pulmonary vein ostia. Circ Arrhythm Electrophysiol. 2013;6:16–22.
23. Shirokova N.V., Turov A.N., Pokushalov E.A., Selina V.V., Romanov A.B. Long-term subcutaneous monitoring of the electrocardiogram to assess the effectiveness of atrial fibrillation catheter ablation. Arrhythmology Bulletin [Vestnik aritmologii]. 2011;65:5-11. (In Russ.)
24. Heidbuchel H., Verhamme R., Alings M., et al. EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013;34(27):2094-106.
25. Pokushalov E., Romanov A., Corbucci G., Bairamova S., Losik D., Turov A., Shirokova N., Karaskov A., Mittal S., Steinberg J.S. Does atrial fibrillation burden measured by continuous monitoring during the blanking period predict the response to ablation at 12-month follow-up? Heart Rhythm. 2012;Vol. 9(9):1375–1379. DOI: 10.1016/j.hrthm.2012.03.047.
26. Dillier R., Ammar S., Reents T. et al. Safety and Efficacy of Continuous Periprocedural Rivaroxaban for Patients Undergoing Catheter Ablation Procedures: A Retrospective Registry Analysis. Heart Rhythm. 2013;Abstract #PO03-127.
27. Pokushalov E., Romanov A., Katritsis D.G., Artyomenko S., Shirokova N., Karaskov A., Mittal S., Steinberg J.S. Ganglionated plexus ablation vs linear ablation in patients undergoing pulmonary vein isolation for persistent/ long-standing persistent atrial fibrillation: a randomized comparison. Heart Rhythm. 2013;10(9):1280–1286. DOI: 10.1016/j.hrthm.2013.04.016.
28. Lakkireddy D., Reddy M., Swarup V., Baqdunes M.W., Mansour M., Chaloub F., Ruskin J., DiBiase L., Vallakatti A., Janga P., Umbarger L. Uninterrupted rivaroxaban vs. warfarin for periprocedural anticoagulation during atrial fibrillation ablation: A multicentre experience. Heart Rhythm. 2013;10(5S):S74.
29. Mittal S., Pokushalov E., Romanov A., Ferrara M., Arshad A., Musat D., Preminger M., Sichrovsky T., Steinberg J.S. Longterm ECG monitoring using an implantable loop recorder for the detection of atrial fibrillation after cavotricuspid
30. Lakkireddy D., Reddy Y., Di Biase L., et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective study. J Am Coll Cardiol. 2014;63:982–988.
31. isthmus ablation in patients with atrial flutter. Heart Rhythm. 2013;10(11):1598–1604. DOI: 10.1016/j.hrthm.2013.07.044.
32. Cappato R., Marchlinski F.E., Hohnloser S.H. et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015 Jul 21;36(28):1805-11. https://doi.org/10.1093/eurheartj/ehv177.
33. Bairamova S.A., Romanov A.B., Mittel S., Mussat D., Steinberg D., Pokushalov E.A. The implantable apparatus for long-term ECG monitoring to detect atrial fibrillation after ablation of the cavotricuspidal isthmus in patients with atrial flutter. Circulatory pathology and cardiac surgery [Patologija krovoobrashhenija i kardiohirurgija]. 2015;19(3):100–109. (In Russ.)
34. Shirokova N.V., Turov A.N., Pokushalov E.A., Selina V.V., Romanov A.B. Long-term subcutaneous monitoring of the electrocardiogram to assess the effectiveness of atrial fibrillation catheter ablation. Arrhythmology Bulletin [Vestnik aritmologii]. 2011;65:5-11. (In Russ.)
35. Pokushalov E., Romanov A., Corbucci G., Bairamova S., Losik D., Turov A., Shirokova N., Karaskov A., Mittal S., Steinberg J.S. Does atrial fibrillation burden measured by continuous monitoring during the blanking period predict the response to ablation at 12-month follow-up? Heart Rhythm. 2012;Vol. 9(9):1375–1379. DOI: 10.1016/j.hrthm.2012.03.047.
36. Pokushalov E., Romanov A., Katritsis D.G., Artyomenko S., Shirokova N., Karaskov A., Mittal S., Steinberg J.S. Ganglionated plexus ablation vs linear ablation in patients undergoing pulmonary vein isolation for persistent/ long-standing persistent atrial fibrillation: a randomized comparison. Heart Rhythm. 2013;10(9):1280–1286. DOI: 10.1016/j.hrthm.2013.04.016.
37. Mittal S., Pokushalov E., Romanov A., Ferrara M., Arshad A., Musat D., Preminger M., Sichrovsky T., Steinberg J.S. Longterm ECG monitoring using an implantable loop recorder for the detection of atrial fibrillation after cavotricuspid
38. isthmus ablation in patients with atrial flutter. Heart Rhythm. 2013;10(11):1598–1604. DOI: 10.1016/j.hrthm.2013.07.044.
39. Bairamova S.A., Romanov A.B., Mittel S., Mussat D., Steinberg D., Pokushalov E.A. The implantable apparatus for long-term ECG monitoring to detect atrial fibrillation after ablation of the cavotricuspidal isthmus in patients with atrial flutter. Circulatory pathology and cardiac surgery [Patologija krovoobrashhenija i kardiohirurgija]. 2015;19(3):100–109. (In Russ.)
Review
For citations:
Zemlyanskaya O.A., Kropacheva E.S. ASPECTS OF MULTICOMPONENT THERAPY AND PERIOPERATIVE TACTICS IN A PATIENT WITH ATRIAL FIBRILLATION RECEIVING RIVAROXABAN THERAPY. CLINICAL OBSERVATION. Aterotromboz = Atherothrombosis. 2019;(1):62-71. (In Russ.) https://doi.org/10.21518/2307-1109-2019-1-62-71
Views:
819
This work is licensed under a Creative Commons Attribution Attribution-NonCommercial-NoDerivs License.
Email this article 